Effect of l-NAME treatment in indomethacin induced gastropathy in iNOS deficient mice
| Group | Lesion index* (mm) | MPO activity* (U/mg) |
|---|---|---|
| *Data are mean (SEM) of 4–6 mice per group. | ||
| iNOS, inducible nitric oxide synthase; MPO, myeloperoxidase. | ||
| ††p<0.01, indomethacin+saline (iNOS−/−) versus indomethacin (wild-type mice). | ||
| ‡‡‡p<0.001, indomethacin+l-NAME (iNOS−/−) versus indomethacin (wild-type mice). | ||
| Vehicle (Tris buffer) | 0.0 (0.0) | 0.64 (0.06) |
| Indomethacin (wild-type mice) | 23.1 (3.7) | 5.36 (0.26) |
| Indomethacin+saline (iNOS−/−) | 12.5 (2.6)†† | 6.46 (1.02) |
| Indomethacin+l-NAME (iNOS−/−) | 9.3 (0.7)‡‡‡ | 8.52 (0.74)‡‡‡ |